Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by New South Capital Management Inc.

New South Capital Management Inc. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 152,363 shares of the medical research company's stock after selling 3,691 shares during the quarter. Thermo Fisher Scientific makes up 3.7% of New South Capital Management Inc.'s portfolio, making the stock its 7th biggest position. New South Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $75,816,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $25,000. Pillar Financial Advisors LLC bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Cassady Schiller Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 89.2% during the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after purchasing an additional 33 shares during the period. Finally, VSM Wealth Advisory LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $36,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Up 0.1%

Shares of NYSE TMO traded up $0.49 during mid-day trading on Friday, hitting $428.25. The company had a trading volume of 1,359,321 shares, compared to its average volume of 1,974,470. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a 50-day simple moving average of $409.18 and a two-hundred day simple moving average of $479.65. The company has a market capitalization of $161.66 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.28 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business's revenue was up .2% compared to the same quarter last year. During the same period last year, the company earned $5.11 earnings per share. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Barclays cut their price objective on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a report on Tuesday, June 24th. Finally, Scotiabank lowered their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research note on Friday, April 25th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $604.05.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.